Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Citi
Farmers Insurance
QuintilesIMS
UBS
Dow
Baxter
McKinsey
Merck

Generated: December 9, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GALLIUM DOTATATE GA-68

« Back to Dashboard

Clinical Trials for Gallium Dotatate Ga-68

Trial ID Title Status Sponsor Phase Summary
NCT01873248 Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients Recruiting Jonsson Comprehensive Cancer Center Phase 1/Phase 2 This is a prospective, Phase 1-2, single center study in a total of 100 subjects with Neuroendocrine Tumors (NETs). Study participants will receive a one-time administration of 68Ga-DOTATATE and undergo a PET/CT imaging study, to investigate its suitability as a PET imaging agent for NETs.
NCT01967537 Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors Recruiting National Cancer Institute (NCI) Phase 2 Background: - Neuroendocrine tumors (NETs) are rare but have been more common over the past decade. The only treatment for NETs is surgery, but most are found when they are too advanced for surgery. Researchers are looking for the best way to find NETs earlier, so that surgery can be successful. They want to test if the study drug can be used along with imaging devices to detect NETs. Objectives: - To see how well a new experimental imaging agent, 68Gallium-DOTATATE, detects unknown primary and metastatic NETs in the gastrointestinal system and pancreas. Eligibility: - Adults over 10 years old with a suspected NET or family history of NET. Design: - Participants will be screened with a medical history and physical exam, and have a blood test. - Participants will undergo three scans. For all of these, a substance is injected into their body, they lie on a table, and a machine takes images. - A standard CT scan of the chest, abdomen, and pelvis. - An octreotide scintigraphy SPECT/CT. - A 68Gallium-DOTATATE PET/CT. The study drug is injected into a vein, usually in the arm. Low-dose X-rays go through the body. For about 40 minutes a large, donut-shaped device takes images of the body. The entire session takes 90 to 120 minutes. - Researchers will compare images from the three scans. - Participants will have 1 follow-up visit each year for 5 years. At this visit, they will have a medical exam, blood taken, and a CT scan.
NCT02078843 Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors Terminated SWAN Isotopen AG, Bern Phase 1/Phase 2 The investigators hypothesize that the new imaging method Gallium-68-DOTATATE has a higher diagnostic value in the detection of neuroendocrine tumors than the established imaging method Indium-111-Octreoscan. Therefore, the investigators will perform both imaging procedures in patients with suspected or confirmed neuroendocrine tumors. Subsequently, the investigators will compare the diagnostic performance of both methods.
NCT02078843 Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors Terminated University Hospital, Basel, Switzerland Phase 1/Phase 2 The investigators hypothesize that the new imaging method Gallium-68-DOTATATE has a higher diagnostic value in the detection of neuroendocrine tumors than the established imaging method Indium-111-Octreoscan. Therefore, the investigators will perform both imaging procedures in patients with suspected or confirmed neuroendocrine tumors. Subsequently, the investigators will compare the diagnostic performance of both methods.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Gallium Dotatate Ga-68

Condition Name

Condition Name for Gallium Dotatate Ga-68
Intervention Trials
Neuroendocrine Tumors 3
Gastroenteropancreatic Neuroendocrine Tumors 2
Hippel-Lindau Disease 1
Von Hippel-Lindau Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Gallium Dotatate Ga-68
Intervention Trials
Carcinoid Tumor 7
Neuroendocrine Tumors 6
Pancreatic Neoplasms 3
Stomach Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Gallium Dotatate Ga-68

Trials by Country

Trials by Country for Gallium Dotatate Ga-68
Location Trials
United States 4
Canada 1
France 1
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Gallium Dotatate Ga-68
Location Trials
Georgia 1
Iowa 1
Maryland 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Gallium Dotatate Ga-68

Clinical Trial Phase

Clinical Trial Phase for Gallium Dotatate Ga-68
Clinical Trial Phase Trials
Phase 2/Phase 3 1
Phase 2 2
Phase 1/Phase 2 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Gallium Dotatate Ga-68
Clinical Trial Phase Trials
Recruiting 4
Not yet recruiting 3
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Gallium Dotatate Ga-68

Sponsor Name

Sponsor Name for Gallium Dotatate Ga-68
Sponsor Trials
National Cancer Institute (NCI) 2
University Hospital Inselspital, Berne 1
University of Alabama at Birmingham 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Gallium Dotatate Ga-68
Sponsor Trials
Other 11
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Fuji
Healthtrust
Citi
Baxter
Fish and Richardson
Daiichi Sankyo
Accenture
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.